SunLink Health Systems, Inc. (NYSE MKT: SSY) today announced a loss from continuing operations for its third fiscal quarter ended March 31, 2015 of $316,000 or a loss of $0.03 per fully diluted share, compared to a loss from continuing operations of $576,000 or a loss of $0.06 per fully diluted share, for the quarter ended March 31, 2014. SunLink reported a net loss for the quarter ended March 31, 2015 of $411,000, or a loss of $0.04 per fully diluted share, compared to a net loss of $964,000, or $0.10 per fully diluted share, for the quarter ended March 31, 2014.
Consolidated net revenues from continuing operations for the quarters ended March 31, 2015 and 2014 were $23,351,000 and $24,466,000, respectively, a decrease of 4.6% in the current year’s quarter from the comparable quarter of fiscal 2014. The Healthcare Facilities Segment net revenues in the current quarter of $13,850,000 decreased $267,000, or 1.9%, compared to $14,117,000 for the comparable quarter of the prior year due to decreased patient equivalent admissions. The Specialty Pharmacy Segment revenues of $9,307,000 in the quarter ended March 31, 2015 decreased $910,000, or 8.9%, from the comparable quarter of the prior year due primarily to lower Medicaid net revenues.
The company reported an operating loss from continuing operations for the quarter ended March 31, 2015 of $285,000, compared to an operating loss from continuing operations for the quarter ended March 31, 2014 of $465,000. Adjusted EBITDA (a non-GAAP measure of the liquidity of the company) for SunLink’s Healthcare Facilities Segment decreased to $543,000 in the three months ended March 31, 2015 from $604,000 for the comparable quarter of the last fiscal year. Adjusted EBITDA for the three months ended March 31, 2015 for the Specialty Pharmacy Segment was $347,000 compared to $709,000 for the comparable quarter in the prior fiscal year.
For the nine months ended March 31, 2015, SunLink reported earnings from continuing operations of $562,000, or $0.06 per fully diluted share, compared to a loss of $1,006,000, or a loss of $0.11 per fully diluted share, for the comparable period of the prior fiscal year. For the nine months ended March 31, 2015, SunLink reported net earnings of $153,000, or $0.02 per fully diluted share, compared to a net loss of $1,895,000 or a loss of $0.20 per share, for the nine months ended March 31, 2014.
Consolidated net revenues from continuing operations for the nine months ended March 31, 2015 decreased by 2.2% to $68,853,000 compared to $70,375,000 in the comparable period a year ago. The Healthcare Facilities Segment had net revenues in the nine months ended March 31, 2015 of $43,169,000 compared to $43,671,000 for the comparable period a year ago. The Specialty Pharmacy Segment had $25,191,000 of net revenues for the nine months ended March 31, 2015 compared to $26,385,000 for the comparable nine months of the prior fiscal year.
SunLink had an operating profit from continuing operations for the nine months ended March 31, 2015 of $2,042,000 compared to an operating loss of $510,000 for the nine months ended March 31, 2014. Adjusted EBITDA for SunLink’s Healthcare Facilities Segment was $4,637,000 in the nine months ended March 31, 2015, compared to $3,489,000 for the comparable period last year. Adjusted EBITDA for the nine months ended March 31, 2015 for the Specialty Pharmacy Segment was $911,000 compared to $1,181,000 for the comparable period last year.
SunLink Health Systems, Inc. is the parent company of subsidiaries that operate hospitals and related businesses in the Southeast, and a specialty pharmacy company in Louisiana. Each hospital is the only hospital in its community and is operated locally with a strategy of linking patients’ needs with dedicated physicians and healthcare professionals to deliver quality efficient medical care. For additional information on SunLink Health Systems, Inc., please visit the company’s website at www.sunlinkhealth.com.
This press release may contain certain statements of a forward-looking nature. The statements contained herein which are not historical facts are considered forward-looking statements under federal securities laws. Such forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently available to them. The company has no obligation to update such forward-looking statements. Actual results may vary significantly from these forward-looking statements.
Adjusted earnings before income taxes, interest, depreciation and amortization
Earnings before income taxes, interest, depreciation and amortization (“EBITDA”) represent the sum of income before income taxes, interest, depreciation and amortization. We understand that certain industry analysts and investors generally consider EBITDA to be one measure of the liquidity of the company, and it is presented to assist analysts and investors in analyzing the ability of the company to generate cash, service debt and meet capital requirements. We believe increased EBITDA is an indicator of improved ability to service existing debt and to satisfy capital requirements. EBITDA, however, is not a measure of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income as a measure of operating performance or to cash liquidity. Because EBITDA is not a measure determined in accordance with accounting principles generally accepted in the United States of America and is thus susceptible to varying calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other corporations. Net cash provided by operations for the three and nine months ended March 31, 2015, respectively, is shown below. Healthcare Facilities Adjusted EBITDA and Specialty Pharmacy Adjusted EBITDA is the EBITDA for those facilities without any allocation of corporate overhead, impairment charges and gains on sale of businesses.
| Three Months Ended | Nine Months Ended | |||||||||||||||||
| March 31, | March 31, | |||||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||||
Healthcare Facilities Adjusted EBITDA | $ | 543,000 | $ | 604,000 | $ | 4,637,000 | $ | 3,489,000 | ||||||||||
| Specialty Pharmacy Adjusted EBITDA | 347,000 | 709,000 | 911,000 | 1,181,000 | ||||||||||||||
| Corporate overhead (costs) | (573,000 | ) | (1,005,000 | ) | (1,689,000 | ) | (2,870,000 | ) | ||||||||||
| Taxes and interest (expense) benefit | (44,000 | ) | (234,000 | ) | 308,000 | (914,000 | ) | |||||||||||
| Other non-cash (expenses) and net increase | ||||||||||||||||||
| (decrease) in operating assets and liabilities | 1,071,000 | (300,000 | ) | (2,875,000 | ) | 2,433,000 | ||||||||||||
| Net cash provided by (used in) operations | $ | 1,344,000 | $ | (226,000 | ) | $ | 1,292,000 | $ | 3,319,000 | |||||||||
| SUNLINK HEALTH SYSTEMS, INC. ANNOUNCES | ||||||||||||||||||||||||||||||||
| FISCAL 2015 THIRD QUARTER AND ANNUAL | ||||||||||||||||||||||||||||||||
| RESULTS | ||||||||||||||||||||||||||||||||
| Amounts in 000's, except per share and volume amounts | ||||||||||||||||||||||||||||||||
| CONSOLIDATED STATEMENTS OF EARNINGS | ||||||||||||||||||||||||||||||||
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||||||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||||||||||||||||||
| % of Net | % of Net | % of Net | % of Net | |||||||||||||||||||||||||||||
| Amount | Revenues | Amount | Revenues | Amount | Revenues | Amount | Revenues | |||||||||||||||||||||||||
| Operating revenues (net of contractual allowances) | $ | 25,196 | 107.9 | % | $ | 26,303 | 107.5 | % | $ | 74,913 | 108.8 | % | $ | 76,500 | 108.7 | % | ||||||||||||||||
| Less provision for bad debts of Healthcare Facilities Segment | 1,845 | 7.9 | % | 1,837 | 7.5 | % | 6,060 | 8.8 | % | 6,125 | 8.7 | % | ||||||||||||||||||||
| Net Revenues | 23,351 | 100.0 | % | 24,466 | 100.0 | % | 68,853 | 100.0 | % | 70,375 | 100.0 | % | ||||||||||||||||||||
| Costs and Expenses: | ||||||||||||||||||||||||||||||||
| Cost of goods sold | 6,181 | 26.5 | % | 7,078 | 28.9 | % | 16,253 | 23.6 | % | 17,838 | 25.3 | % | ||||||||||||||||||||
| Salaries, wages and benefits | 10,729 | 45.9 | % | 10,591 | 43.3 | % | 32,135 | 46.7 | % | 32,105 | 45.6 | % | ||||||||||||||||||||
| Provision for bad debts of Specialty Pharmacy Segment | 65 | 0.3 | % | 75 | 0.3 | % | 188 | 0.3 | % | 170 | 0.2 | % | ||||||||||||||||||||
| Supplies | 1,877 | 8.0 | % | 1,808 | 7.4 | % | 6,017 | 8.7 | % | 5,790 | 8.2 | % | ||||||||||||||||||||
| Purchased services | 1,208 | 5.2 | % | 1,289 | 5.3 | % | 3,410 | 5.0 | % | 3,884 | 5.5 | % | ||||||||||||||||||||
| Other operating expenses | 2,695 | 11.5 | % | 2,994 | 12.2 | % | 7,035 | 10.2 | % | 8,967 | 12.7 | % | ||||||||||||||||||||
| Rents and leases | 343 | 1.5 | % | 366 | 1.5 | % | 1,020 | 1.5 | % | 1,079 | 1.5 | % | ||||||||||||||||||||
| Insurance settlement | 0 | 0.0 | % | 0 | 0.0 | % | (1,000 | ) | -1.5 | % | 0 | 0.0 | % | |||||||||||||||||||
| Depreciation and amortization | 602 | 2.6 | % | 773 | 3.2 | % | 1,817 | 2.6 | % | 2,310 | 3.3 | % | ||||||||||||||||||||
| Electronic Health Records incentive payments | (64 | ) | -0.3 | % | (43 | ) | -0.2 | % | (64 | ) | -0.1 | % | (1,258 | ) | -1.8 | % | ||||||||||||||||
| Operating Profit (Loss) | (285 | ) | -1.2 | % | (465 | ) | -1.9 | % | 2,042 | 3.0 | % | (510 | ) | -8.3 | % | |||||||||||||||||
| Gain on sale of assets | 13 | 0.1 | % | 18 | 0.1 | % | 13 | 0.0 | % | 18 | 0.1 | % | ||||||||||||||||||||
| Interest Expense - net | (213 | ) | -0.9 | % | (234 | ) | -1.0 | % | (677 | ) | -1.0 | % | (714 | ) | -1.0 | % | ||||||||||||||||
| Earnings (Loss) from Continuing Operations before income taxes | (485 | ) | -2.1 | % | (681 | ) | -2.8 | % | 1,378 | 2.0 | % | (1,206 | ) | -1.7 | % | |||||||||||||||||
| Income Tax Expense (Benefit) | 169 | 0.7 | % | (105 | ) | -0.4 | % | 816 | 1.2 | % | (200 | ) | -0.3 | % | ||||||||||||||||||
| Earnings (Loss) from Continuing Operations | (316 | ) | -1.4 | % | (576 | ) | -2.4 | % | 562 | 0.8 | % | (1,006 | ) | -1.4 | % | |||||||||||||||||
| Loss from Discontinued Operations, net of tax | (95 | ) | -0.4 | % | (388 | ) | -1.6 | % | (409 | ) | -0.6 | % | (889 | ) | -1.3 | % | ||||||||||||||||
| Net Loss | $ | (411 | ) | -1.8 | % | $ | (964 | ) | -3.9 | % | $ | 153 | 0.2 | % | $ | (1,895 | ) | -2.7 | % | |||||||||||||
| Earnings (Loss) Per Share from Continuing Operations: | ||||||||||||||||||||||||||||||||
| Basic | $ | (0.03 | ) | $ | (0.06 | ) | $ | 0.06 | $ | (0.11 | ) | |||||||||||||||||||||
| Diluted | $ | (0.03 | ) | $ | (0.06 | ) | $ | 0.06 | $ | (0.11 | ) | |||||||||||||||||||||
| Loss Per Share from Discontinued Operations: | ||||||||||||||||||||||||||||||||
| Basic | $ | (0.01 | ) | $ | (0.04 | ) | $ | (0.04 | ) | $ | (0.09 | ) | ||||||||||||||||||||
| Diluted | $ | (0.01 | ) | $ | (0.04 | ) | $ | (0.04 | ) | $ | (0.09 | ) | ||||||||||||||||||||
| Net Earnings (Loss) Per Share: | ||||||||||||||||||||||||||||||||
| Basic | $ | (0.04 | ) | $ | (0.10 | ) | $ | 0.02 | $ | (0.20 | ) | |||||||||||||||||||||
| Diluted | $ | (0.04 | ) | $ | (0.10 | ) | $ | 0.02 | $ | (0.20 | ) | |||||||||||||||||||||
| Weighted Average Common Shares Outstanding: | ||||||||||||||||||||||||||||||||
| Basic | 9,443 | 9,443 | 9,443 | 9,443 | ||||||||||||||||||||||||||||
| Diluted | 9,433 | 9,443 | 9,481 | 9,443 | ||||||||||||||||||||||||||||
| HEALTHCARE FACILITIES VOLUME STATISTICS | ||||||||||||||||||||||||||||||||
| Admissions | 621 | 636 | 1,913 | 1,869 | ||||||||||||||||||||||||||||
| Equivalent Admissions | 1,673 | 1,968 | 5,409 | 5,981 | ||||||||||||||||||||||||||||
| Surgeries | 381 | 481 | 1,209 | 1,340 | ||||||||||||||||||||||||||||
| Net revenue per equivalent admission | $ | 8,279 | $ | 7,173 | $ | 7,981 | $ | 7,271 | ||||||||||||||||||||||||
| SUMMARY BALANCE SHEETS | ||||||||||||||||||||||||||||||||
| March 31, | June 30, | |||||||||||||||||||||||||||||||
| ASSETS | 2015 | 2014 | ||||||||||||||||||||||||||||||
| Cash and Cash Equivalents | $ | 4,885 | $ | 3,587 | ||||||||||||||||||||||||||||
| Accounts Receivable - net | 10,018 | 9,850 | ||||||||||||||||||||||||||||||
| Other Current Assets | 10,027 | 12,338 | ||||||||||||||||||||||||||||||
| Property Plant and Equipment, net | 22,537 | 23,077 | ||||||||||||||||||||||||||||||
| Long-term Assets | 9,956 | 14,995 | ||||||||||||||||||||||||||||||
| $ | 57,423 | $ | 63,847 | |||||||||||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||||||||||||||
| Current Liabilities | $ | 10,697 | $ | 16,506 | ||||||||||||||||||||||||||||
| Long-term Debt and Other Noncurrent Liabilities | 13,221 | 14,023 | ||||||||||||||||||||||||||||||
| Shareholders' Equity | 33,505 | 33,318 | ||||||||||||||||||||||||||||||
| $ | 57,423 | $ | 63,847 | |||||||||||||||||||||||||||||
Contacts:
Robert M. Thornton, Jr.,
770-933-7004
Chief Executive Officer
